Genovis won the SwedenBIO award

High-quality research, global presence and a sense of humor - this is how the company Genovis, which won the SwedenBIO Award for 2023, is described.

Genovis CEO Fredrik Olsson accepted the award at an award ceremony during the SwedenBIO Summit at the Grand Hôtel in Stockholm on January 30.

Genovis was founded in 1999 and has grown significantly since then. The company develops and delivers innovative enzyme and antibody solutions that enable higher efficiency in the development and characterization of biopharmaceutical and ATMP products. With a focus on the customer, the company has established a global presence and entered into several international partnerships, which has benefited product development. Genovis went to market with a unique combination of high-quality research and humor, which is now a successful part of their brand.

“The award is a fantastic recognition after years of teamwork to develop Genovis. We have been very good at building the company over the years and becoming internationally successful,” said Fredrik Olsson, CEO of Genovis.

The SwedenBIO Award is presented annually in collaboration with HealthCap to a life science company that has shown outstanding performance and contribution to society and that exemplifies the potential of a strong Swedish life science industry. This year’s three finalists were Genovis, Xbrane Biopharma and Pelago BioScience.

“Life science is a tough industry where success doesn’t come easy, so it’s important to celebrate when things go right. “Sponsoring the SwedenBIO award is our way of bringing people together to celebrate when things are going well,” said Carl Kilander, Partner at HealthCap, who presented the award on stage during the Summit.

The jury consisted of the SwedenBIO board: Lotta Ljungqvist, 4L Bioconsulting; Christine Wesström, Sobi; Anders Persson, AstraZeneca; Kerstin Falck, Pfizer; Mårten Winge, Strike Pharma; Niels Abel Bonde, Novo Nordisk Sweden; Carl Kilander, HealthCap; Sana Alajmovic, Sigrid Therapeutics; and Torkel Gren, Recipharm.